Plasma Cell Leukemia
📧 Sign up to get email alerts when something new happens for Plasma Cell Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating CAR.70, engineered IL-15-transduced cord blood-derived natural killer (NK) cells, in combination with…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial evaluating adaptive dual-target CAR-T cell therapy for relapsed or refractory hematologic malignancies; recru…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia [Phase 2]
Phase 2 clinical trial evaluating IL-15-Armored CAR-T therapy in relapsed or refractory multiple myeloma and plasma cell leukemia; currently…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating whether budesonide reduces the incidence of grade 2 or higher diarrhea in multiple myeloma patients underg…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia [Phase 2]
A Phase 2 clinical trial is evaluating a VRD-based regimen in combination with CART-ASCT-CART2 therapy for primary plasma cell leukemia and …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Expanded Access to Venetoclax
Expanded access to venetoclax is being offered for multiple hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, A…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
This clinical trial update notes that IASO104 is being evaluated in an early-phase 1 study for relapsed/refractory multiple myeloma and plas…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
A registry study to evaluate cancer and aging resilience in older adults with hematologic malignancies, including multiple myeloma, amyloido…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: European Myeloma Network (EMN) Sample Project
A European Myeloma Network study evaluating treatment options for multiple myeloma and related plasma cell disorders is currently recruiting…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma [Phase 2]
Phase 2 trial evaluating isatuximab, dexamethasone, and lenalidomide in ultra-frail patients with multiple myeloma and plasma cell leukemia,…
-
CLINICAL_TRIALS withdrawal · 2025-10-15Clinical Trial Update: Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma [Phase 1]
A Phase 1 trial of bendamustine hydrochloride in previously treated multiple myeloma and plasma cell leukemia has been withdrawn.
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating CT0596 in relapsed/refractory multiple myeloma and relapsed/refractory plasma cell leukemia is cu…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia [NA]
This ClinicalTrials.gov entry updates a study that uses high-throughput drug sensitivity and genomics to guide individualized treatment for …
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 [Phase 2]
This update reports the completion of a Phase 2 clinical trial evaluating treatment for primary plasma cell leukemia in patients under 70.
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients [Phase 1]
Phase 1 trial evaluating Itacitinib with high-dose posttransplantation cyclophosphamide in older patients. The study is currently ACTIVE_NOT…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM [Phase 1, Phase 2]
A Phase 1/2 clinical trial in China evaluating autologous stem cell transplantation combined with BCMA CAR-T therapy for ultra high risk mul…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia [Phase 2]
A Phase 2 clinical trial evaluating autologous stem cell transplant (ASCT) followed by maintenance with BCMA CAR-T cells and GPRC5D/CD3 BiTE…
-
CLINICAL_TRIALS research · 2025-08-03Clinical Trial Update: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia [Phase 2]
This Phase 2 clinical trial from China tests a bortezomib-lenalidomide-dexamethasone regimen followed by BCMA CAR-T therapy in transplant-in…
-
CLINICAL_TRIALS research · 2025-08-01Clinical Trial Update: A Study of CT0596 in Plasma Cell Leukemia [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating CT0596 for plasma cell leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research [EARLY_Phase 1]
This document reports an EARLY Phase 1 clinical trial evaluating Meta10-BCMA for relapsed/refractory plasma cell neoplasms. The therapy uses…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia [Phase 1]
A Phase 1 clinical trial evaluating CAR-GPRC5D in relapsed/refractory multiple myeloma or plasma cell leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-20Clinical Trial Update: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia [Phase 1]
This Clinical Trial Update describes a Phase 1 study evaluating CAR-GPRC5D cell therapy in patients with relapsed/refractory multiple myelom…
-
CLINICAL_TRIALS research · 2025-05-11Clinical Trial Update: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy [Phase 1]
This document provides a status update for a Phase 1 clinical trial evaluating the SVN53-67/M57-KLH peptide vaccine in newly diagnosed multi…
-
CLINICAL_TRIALS trial_result · 2025-05-09Clinical Trial Update: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 trial evaluating cord blood-derived natural killer cells in combination with elotuzumab, lenalidomide, high-dose melphalan, and stem…
-
CLINICAL_TRIALS research · 2025-04-25Clinical Trial Update: Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia [Phase 2]
Phase 2 clinical trial evaluating ARI0002h for initial treatment of primary plasma cell leukemia; the study is currently not yet recruiting.